Screening strategy of High grade B-cell lymphoma

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K07396
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 49020:Human pathology-related
• Research Institution: Saitama Medical University
• Principal Investigator: Momose Shuji 埼玉医科大学, 医学部, 教授 (70360344)
• Co-Investigator(Kenkyū-buntansha): 森 隆 埼玉医科大学, 医学部, 教授 (60239605)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: DLBCL / Burkitt lymphoma

Outline of Final Research Achievements

High-grade B-cell lymphoma (HGBL) is one of the disease entities that exert a worse prognosis among B-cell lymphomas. Currently, the diagnosis of high-grade B-cell lymphoma cannot be made without molecular genetic analysis of MYC, BCL2, and BCL6 by fluorescence in situ hybridization. This study attempts to extract high-grade B-cell lymphomas immunohistochemically without performing the FISH method. Several factors were isolated, and an attempt was made to extract the poor prognosis group by referring to the previously published literature and the gene expression profile data of the applicants. As a result, three factors were used to extract the poor prognosis group, suggesting the possibility of an alternative method using immunohistochemistry.

Free Research Field

診断病理

Academic Significance and Societal Importance of the Research Achievements

高悪性度B細胞リンパ腫はB細胞リンパ腫の中でも最も予後の悪い疾患単位の一つであるが、その診断法は、現在のところ分子遺伝学的に MYC，BCL2，BCL6 の再構成の検索なしには確定しえない。本研究では既報の文献や申請者らの遺伝子発現プロファイルデータを参考に、複数因子を抽出し、予後不良群の抽出の試みを行った。その結果、免疫組織化学による３つの因子の発現により予後不良群が抽出された。このことは免疫組織化学による代替法の可能性が示唆され、将来的には治療階層化の一助となることが期待された。